Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) was the recipient of a large decline in short interest in the month of October. As of October 13th, there was short interest totalling 573,008 shares, a decline of 20.6% from the September 29th total of 721,680 shares. Based on an average daily trading volume, of 49,508 shares, the days-to-cover ratio is presently 11.6 days. Approximately 2.5% of the company’s shares are short sold.

Aquinox Pharmaceuticals (AQXP) opened at 11.93 on Friday. Aquinox Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $19.97. The stock has a 50 day moving average price of $13.67 and a 200-day moving average price of $14.14. The firm’s market capitalization is $279.93 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.59). Analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Archon Partners LLC boosted its holdings in shares of Aquinox Pharmaceuticals by 44.0% during the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Aquinox Pharmaceuticals by 4.7% during the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Aquinox Pharmaceuticals by 16.5% during the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Aquinox Pharmaceuticals during the second quarter worth about $874,000. Finally, Northern Trust Corp boosted its holdings in shares of Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares during the period. Institutional investors own 95.15% of the company’s stock.

Several research analysts have commented on the company. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $22.25.

COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals Inc (AQXP) Sees Significant Decrease in Short Interest” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/29/aquinox-pharmaceuticals-inc-aqxp-sees-significant-decrease-in-short-interest.html.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.